09.05.2018 CO.DON AG  DE000A1K0227

DGAP-News: CO.DON AG: First Spherox transplantation successfully performed in Great Britain


 
DGAP-News: CO.DON AG / Key word(s): Expansion CO.DON AG: First Spherox transplantation successfully performed in Great Britain 09.05.2018 / 09:59 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- First Spherox transplantation successfully performed in Great Britain Berlin / Teltow, 9 Mai 2018 - At the Royal Orthopaedic Hospital (ROH), Birmingham, one of the leading British orthopaedic centres, the first patient in Great Britain was treated with the autologous cartilage repair product Spherox. Last week, Professor Martyn Snow, Consultant Orthopaedic Surgeon at the ROH, transplanted the EU-wide authorized product. The 31-year-old patient injured his knee during sport six years ago. Professor Snow explained that there are limited options available for treating cartilage defects larger than 2 cm2 and that the ROH is very pleased to have this new treatment option and to be the first hospital in the UK to use it. The body's own cell therapy product could help many patients who are qualified for the treatment. The British National Institute for Health and Care Excellence (NICE) estimates that each year around 10,000 people in the UK are diagnosed with cartilage damage that falls under the indication of the cell therapy product offered by CO.DON. While smaller injuries can be treated successfully with other methods, those with mid- to larger injuries to their cartilage would benefit from this novel treatment. CO.DON AG develops, produces and markets autologous cell therapies for the minimally-invasive repair of cartilage defects in the knee following traumatic or degenerative defects. Spherox is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). The treatment has been used in over 200 clinics to treat more than 12,000 patients. In July 2017 the company received EU marketing authorisation for Spherox. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs. Further information is available from: www.codon.eu Investor Relations and Press Contact: Matthias Meißner, M.A. Corporate communications / IR / PR Tel. +49 (0)30 240352330 Fax +49 (0)30 240352309 Email: ir@codon.de --------------------------------------------------------------------------- 09.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: CO.DON AG Warthestraße 21 14513 Teltow Germany Phone: 03328 43460 Fax: 03328 434643 E-mail: info@codon.de Internet: www.codon.de ISIN: DE000A1K0227 WKN: A1K022 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 684137 09.05.2018


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 2,69 3,62 4,48 5,09 5,60 5,96 5,65 8,80
EBITDA1,2 -2,24 -2,50 -2,27 -2,61 -3,41 -6,73 -7,84 0,00
EBITDA-Marge3 -83,27 -69,06 -50,67 -51,28 -60,89 -112,92 -138,76 0,00
EBIT1,4 -2,38 -2,68 -2,48 -2,86 -3,65 -6,98 -8,56 0,00
EBIT-Marge5 -88,48 -74,03 -55,36 -56,19 -65,18 -117,11 -151,50 0,00
Jahresüberschuss1 -2,38 -2,68 -2,49 -2,87 -3,65 -7,05 -6,27 0,00
Netto-Marge6 -88,48 -74,03 -55,58 -56,39 -65,18 -118,29 -110,97 0,00
Cashflow1,7 -2,33 -1,56 -1,78 -2,97 -3,62 -5,88 -8,14 0,00
Ergebnis je Aktie8 -0,22 -0,24 -0,18 -0.18 -0,21 -0,36 -0,55 -0,74
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
co.don
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1K022 4,230 84,70
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,000 -13,16
KBV KCV KUV EV/EBITDA
6,69 - 14,98 -9,497
Dividende '17 in € Dividende '18 in € Div.-Rendite '18
in %
Hauptversammlung
0,00 0,00 0,00 12.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.08.2019 30.04.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-5,26% -4,58% 33,23% -30,08%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CO.DON AG  ISIN: DE000A1K0227 können Sie bei DGAP abrufen

Biotechnologie , A1K022 , CNWK , XETR:CNWK